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Whole-genome sequencing (WGS) could potentially provide a single platform for extracting all the information required to pre-
dict an organism’s phenotype. However, its ability to provide accurate predictions has not yet been demonstrated in large inde-
pendent studies of specific organisms. In this study, we aimed to develop a genotypic prediction method for antimicrobial sus-
ceptibilities. The whole genomes of 501 unrelated Staphylococcus aureus isolates were sequenced, and the assembled genomes
were interrogated using BLASTn for a panel of known resistance determinants (chromosomal mutations and genes carried on
plasmids). Results were compared with phenotypic susceptibility testing for 12 commonly used antimicrobial agents (penicillin,
methicillin, erythromycin, clindamycin, tetracycline, ciprofloxacin, vancomycin, trimethoprim, gentamicin, fusidic acid, rifam-
pin, and mupirocin) performed by the routine clinical laboratory. We investigated discrepancies by repeat susceptibility testing
and manual inspection of the sequences and used this information to optimize the resistance determinant panel and BLASTn
algorithm. We then tested performance of the optimized tool in an independent validation set of 491 unrelated isolates, with
phenotypic results obtained in duplicate by automated broth dilution (BD Phoenix) and disc diffusion. In the validation set, the
overall sensitivity and specificity of the genomic prediction method were 0.97 (95% confidence interval [95% CI], 0.95 to 0.98)
and 0.99 (95% CI, 0.99 to 1), respectively, compared to standard susceptibility testing methods. The very major error rate was
0.5%, and the major error rate was 0.7%. WGS was as sensitive and specific as routine antimicrobial susceptibility testing meth-
ods. WGS is a promising alternative to culture methods for resistance prediction in S. aureus and ultimately other major bacte-
rial pathogens.
Whole-genome sequencing (WGS) is a rapidly advancingtechnology, and increasingly affordable benchtop sequenc-
ers could be in use in the routine clinical laboratory within the
next decade (1). It may soon be practical to sequence specimens
directly in a matter of hours, resulting in enormous diagnostic
improvements and creating new challenges for the routine labo-
ratory (2). One key application is likely to be antimicrobial resis-
tance prediction from the genome sequence (“resistance geno-
type”), analogous to in silico multiplex PCR for a large number of
known resistance genes. It is theoretically possible to recover the
entire complement of genes encoding resistance from the
genomic sequence of an isolate in a single step. Recently, Zankari
et al. (3) and Stoesser et al. (4) reported on resistance prediction
using a simple BLAST method. Despite the limited size and lack of
independent validation in these studies, they provide intriguing
hints that much phenotypic resistance may be simply explained
using genotypic prediction from WGS.
To be used confidently in clinical practice, reliable genotypic
prediction of antimicrobial resistance phenotype has to be dem-
onstrated to the same standards as any new phenotypic method,
using large diverse sets of unrelated isolates. Comprehensively val-
idated genotypic prediction of antimicrobial resistance, ready for
implementation in clinical practice, will require multiple large
studies. However, early investigation of the performance of
known genetic determinants for resistance prediction could estab-
lish the feasibility of this approach.
In this study, we describe a three-step approach for developing
a resistance gene prediction method using Staphylococcus aureus,
with (i) initial development using easily available bioinformatics
algorithms and a “derivation set” of 501 isolates, (ii) testing and
algorithm refinement, and (iii) validation of the method in a fur-
ther unrelated set of 491 isolates.
MATERIALS AND METHODS
Creation of a catalogue of antimicrobial resistance genes. A panel of
antimicrobial agents (Tables 1 and 2) was identified for investigation
based on those used routinely for management of S. aureus infections in
the Oxford University Hospitals (OUH) National Health Service (NHS)
Trust. To identify the genetic determinants encoding resistance to these
antimicrobial agents, a literature search was conducted in PubMed using
the medical subject heading (MESH) terms “Staphylococcus aureus” and
“Drug resistance, microbial” and individual antimicrobial drug names to
create a catalogue of antimicrobial resistance genes and variants, using
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published sequences deposited in GenBank (http://www.ncbi.nlm.nih
.gov/GenBank/).
Whole-genome sequencing, assembly, and resistance gene detec-
tion. Ethical approval for sequencing S. aureus isolates from routine clin-
ical samples and linkage to patient data without individual patient consent
in Oxford and Brighton in the United Kingdom was obtained from Berk-
shire Ethics Committee (10/H0505/83) and the United Kingdom Na-
tional Information Governance Board [8-05(e)/2010]. For all isolates,
DNA was extracted and sequenced using the Illumina HiSeq 2000 plat-
form (San Diego, CA, USA) as previously described (5). To assess se-
quencing quality, reads were mapped to reference strain MRSA 252 (Gen-
Bank accession no. BX571856.1) using Stampy v1.0.18 (6). MRSA 252 was
chosen as it contains staphylococcal cassette chromosomemec (SCCmec),
has been capillary sequenced (7), and belongs to a common United King-
dom methicillin-resistant S. aureus (MRSA) clone (EMRSA 16). To ob-
tain whole genomes for BLAST, reads were then de novo assembled using
Velvet v1.0.18 (8). Samples were excluded if they failed quality checks
either on mapping (70% coverage of reference genome after filtering) or
assembly (50% of the genome in contigs 1 kb).
Initial method development using the derivation set. The de novo-
assembled genomes were interrogated with BLAST (v 2.2.28) blastn
and tblastn (9) to identify nucleotide sequences matching genes from the
TABLE 1 Panel of genes associated with mobile genetic elements used for BLAST querya
Antimicrobial agent(s) Geneb Productc
Reference gene accession no.
(nucleotide positions)
Penicillin blaZ Class A beta-lactamase BX571856.1 (1913827–1914672)
Methicillin mecA Low-affinity PBP2 BX571856.1 (44919–46925)
Erythromycin msrA* Erythromycin resistance protein CP003194 (54168–55634)
Erythromycin and clindamycin ermA rRNA adenine N-6-methyltransferase BA000018.3 (56002–56733)
ermB rRNA adenine N-6-methyltransferase AB699882.1 (4971–5708)
ermC rRNA adenine N-6-methyltransferase HE579068 (7858–8592)
ermT 23S rRNA methylase HF583292 (11344–12078)
Tetracycline tetK MFS tetracycline effux pump FN433596 (69118–70497)
tetL MFS tetracycline efflux pump HF583292 (7713–9089)
tetM Ribosomal protection protein CP002643 (427033–428952)
Vancomycin vanA Low-affinity peptidoglycan precursor AE017171.1
Fusidic acid fusB Fusidic acid detoxification CP003193.1 (1336–1977)
far* Ribosome protection protein AY373761.1 (19072–19713)
Trimethoprim dfrA Insensitive dihydrofolate reductase CP002120 (2093303–2093788)
dfrG Insensitive dihydrofolate reductase FN433596 (502263–502760)
Gentamicin aacA-aphD 6=-aminoglycoside N-acetyltransferase/
2-aminoglycoside phosphotransferase
FN433596.1 (2209531–2210970)
Mupirocin (high-level resistance) mupA Isoleucyl-tRNA synthetase HE579068 (2157–5231)
mupB Isoleucyl-tRNA synthetase JQ231224
a Presence of the gene correlates with phenotypic resistance. Reference sequences were obtained from published sequences from human clinical isolates.
b An asterisk indicates that the gene was added in v2.0.
c MFS, major facilitator superfamily.
TABLE 2 Panel of housekeeping genes with amino acid variants known to be associated with antimicrobial resistancea
Antimicrobial agent Gene Amino acid substitutionsb
Reference gene accession no.
(nucleotide positions)
Ciprofloxacin gyrA S84L, E88K, G106D, S85P, E88G, E88L BX571857.1 (7005–9668)
grlA S80F, S80Y, E84K, E84G, E84V, D432G, Y83N, A116E, I45M, A48T, D79V, V41G, S108N BX571857.1 (1386869–1389271)
grlB R470D*, E422D*, P451S*, P585S*, D443E*, R444S* BX571857.1 (1384872–1386869)
Fusidic acid fusA A160V*, A376V, A655E, A655P*, A655V*, A67T*, A70V*, A71V*, B434N, C473S*,
D189G*, D189V*, D373N*, D463G*, E233Q*, E444K, E444V*, E449K*, F441Y,
F652S*, G451V, G452C, G452S, G556S, G617D, G664S, H438N, H457Q, H457Y,
L430S*, L456F, L461K, L461S, M161I*, M453I, M651I, P114H, P404L, P404Q, P406L,
P478S, Q115L, R464C, R464H, R464S, R659C, R659H, R659L, R659S, R76C*, S416F*,
T385N, T387I*, T436I, T656K, V607I, V90A, V90I, Y654N*
BX571857.1 (577685–579766)
Rifampin rpoB A473T*, A477D, A477T*, A477V, D471G*, D471Y, D550G, H481D, H481N, H481Y,
I527F, I527L*, I527 M*, ins 475H, ins G475*, L466S*, M470T*, N474K*, Q456K,
Q468K, Q468L, Q468R, Q565R*, R484H, S463P, S464P, S486L, S529L*
BX571857 (568813–572364)
Trimethoprim dfrB F99Y, F99S, F99I, H31N, L41F, H150R, L21V*, N60I* BX571857.1 (1464014–1464493)
a All housekeeping gene sequences were obtained from the genome of reference strain MSSA 476 (7).
b An asterisk indicates that the amino acid substitution was reported in association with other variants. For the expected effect of each variant/combination on MIC, please see the
supplemental data. ins, insertion.
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panel and their matching protein sequences, respectively. The parameters
for the two programs were as follows: for blastn, word size of 17, gap
opening penalty of 5, and gap extension penalty of 2; for tblastn, word size
of 3, gap opening penalty of 11, and gap extension penalty of 1. The
E-value cutoff was set at 0.001. Relative coverage was defined as the prod-
uct of the proportion of reference allele matched and the sequence identity
of the match. For the initial algorithm (v1.0), a relative coverage threshold
of80% was chosen to define gene presence with a high degree of simi-
larity to the reference, based on pilot data (for example, 95% relative
coverage may be 95% of the gene length with 100% identity or 100% of the
gene length with 95% identity). For housekeeping genes, where resistance
is conferred by one or more point mutations, differences between the
tblastn result and the query protein sequence were compared to the se-
quence of the wild-type protein and compared against the catalogue of
known antimicrobial resistance-encoding mutations compiled above.
Changes in protein sequence (at the same or different codons) which were
not previously reported as conferring resistance were counted as suscep-
tible.
To determine the diversity of the isolates tested, in silico prediction of
multilocus sequence type (MLST) was also performed using BLAST.
The S. aureus MLST alleles were extracted from assemblies based on se-
quence similarity to allele 1 for each locus, and the online MLST database
(http://saureus.mlst.net/) was used to predict the ST.
The initial development of the algorithm was not done in a blind
manner, using 501 clinical S. aureus isolates which had been sequenced
and phenotyped previously and whose WGS and resistance data were
available (“derivation set”). To ensure a representative range of sequence
types, isolates were identified from bacteremia and carriage collections
held at the Oxford Radcliffe Hospitals NHS Trust and Brighton and Sus-
sex University Hospitals NHS Trust, spanning a period of 13 years (Table
3) (10). The collection included 159 MRSA isolates (32%). All isolates had
been tested at each site by the routine clinical laboratories for resis-
tance to a standard first-line panel of antimicrobial agents (penicillin,
methicillin, erythromycin, vancomycin, ciprofloxacin, tetracycline, gen-
tamicin, fusidic acid, and rifampin at both sites; mupirocin and clinda-
mycin for Brighton isolates only; trimethoprim for Oxford isolates only).
In the Brighton clinical laboratory, susceptibility testing was performed
using the Vitek automated system (bioMérieux, Basingstoke, United
Kingdom), and in the Oxford clinical laboratory, isolates were pheno-
typed by disc diffusion (11). The susceptibility testing results were re-
trieved electronically from laboratory databases. Methicillin resistance
was tested using cefoxitin (Brighton) or oxacillin (Oxford).
Comparison of phenotype and predicted genotypic resistance. The
predicted susceptibilities based on mobile and chromosomal genetic ele-
ments, using the whole-genome sequences of the isolates in the derivation
set, were compared with the routine laboratory susceptibility testing re-
sults. Where there was a mismatch between genotypic prediction and
recorded phenotype, isolates were retrieved from storage at 80°C and
had repeat susceptibility tested by gradient diffusion using EUCAST
breakpoints (http://www.eucast.org/clinical_breakpoints/) to resolve the
phenotype (“discordant repeat”). A very major error (VME) was defined
as a susceptible genotype with a resistant phenotype, and a major error
(ME) was defined as a resistant genotype with a susceptible phenotype.
Revision of bioinformatics algorithm. Using the results obtained
above, we further examined genotype-phenotype mismatches to identify
whether algorithm improvements could be made. We extended the gene
panel by manually searching references from the original search and
added two additional genes to the panel (msrA and far) and added to the
list of variants for fusA. We noted a high VME rate for penicillin and
fusidic acid which was reduced by adjusting the algorithm quality filters to
accept short or low-coverage contigs for blaZ, fusB, and far (see Results for
details). We estimated sensitivity and specificity with different thresholds
for the relative coverage required for these genes to be considered present
in the derivation set. For the revised algorithm (v2.0), the best compro-
mise between overall sensitivity and specificity was obtained by defining
resistance as30% relative coverage for blaZ, fusB, and far and as80%
relative coverage for the remaining mobile genes.
Blind validation of revised prediction method v2.0. Because repeat
susceptibility testing and revision of the genotype prediction algorithm
were done with a priori knowledge of the phenotype, to validate the
method, we applied v2.0 to a further 491 isolates (the “validation set”
[Table 3]), with no previous information regarding the expected pheno-
type available before genotypic interrogation (i.e., blind to phenotype).
A total of 202 isolates were sourced from carriage collections (12)
which had previously been sequenced but not phenotyped. These isolates
were retrieved from storage at80°C for resistance testing. A further 289
isolates were obtained from archived bloodstream collections at the Ox-
ford and Brighton sites. For these, single colonies were plated on Colum-
bia blood agar and grown at 37°C for 18 to 24 h. All the bacteria on the
plate were harvested and suspended in 1.5 ml physiological saline. A por-
tion (0.1 ml) was removed and replated onto Columbia blood agar and
incubated overnight at 37°C for resistance phenotyping, and the remain-
ing suspension was used to prepare DNA for WGS.
To control for differences in phenotypic testing methods, all 491 iso-
TABLE 3 Source of isolates and method of susceptibility testing
Collection
No. of
isolates Sourcea Specimen type Dates Susceptibility testing methods Sequencing
Derivation set
collections
(n 501)
88 Brighton (all wards) Blood 1999–2007 Automated broth dilution
(Vitek), clinical laboratory
Previously sequenced
90 Brighton carriage
(ITU)
Nasal swab 2010–2011 Disc diffusion, clinical laboratory Previously sequenced
323 Oxford (all wards) Blood 2008–2011 Disc diffusion, clinical laboratory Previously sequenced
Validation set
collections
(n 491)
102 Oxford carriage (ITU) Nasal swab 2009 Disc diffusion and automated
broth dilution (BD Phoenix)
Previously sequenced
100 Oxford carriage
(community)
Nasal swab 2009 Disc diffusion and automated
broth dilution (BD Phoenix)
Previously sequenced
165 Brighton (all wards) Blood 2011–2012 Disc diffusion and automated
broth dilution (BD Phoenix)
Sequenced de novo, susceptibility
testing performed from same
subculture as sequencing
124 Oxford (all wards) Blood 2011–2012 Disc diffusion and automated
broth dilution (BD Phoenix)
Sequenced de novo, susceptibility
testing performed from same
subculture as sequencing
a Brighton, Brighton and Sussex University Hospitals NHS Trust; Oxford, Oxford Radcliffe Hospitals NHS Trust; ITU, intensive therapy unit.
Gordon et al.
1184 jcm.asm.org Journal of Clinical Microbiology
lates had antimicrobial susceptibility testing performed by M. Morgan
using the Phoenix automated microbiology system (BD Biosciences,
Sparks, MD, USA) for a standard panel of antimicrobial agents (penicillin,
methicillin, ciprofloxacin, erythromycin, fusidic acid, gentamicin, mupi-
rocin, rifampin, tetracycline, and vancomycin). Isolates were also tested
by disc diffusion (13) by K. Cole and J. R. Price (Brighton isolates, panel as
described above) and N. C. Gordon (Oxford isolates, panel as described
above plus trimethoprim). Concordant results for the two methods were
used as the final phenotype. Isolates that were resistant to erythromycin
were further tested for clindamycin resistance by disc diffusion and the
clindamycin D test (14). Where there was discordance between disc dif-
fusion and BD Phoenix, repeat testing was performed by the gradient
diffusion method (Etest) using EUCAST breakpoints, and this value was
used as the phenotype.
Whole-genome sequences were interrogated by BLAST using the
revised parameters as described above, performed in a blind manner (the
phenotype not known) by T. Golubchik. Finally, the phenotypic and ge-
notypic profiles were compared by a separate investigator (T. E. A. Peto).
The sensitivity, specificity, and error rates (calculated as percentages of the
total number of resistance tests) were calculated against the concordant
phenotype.
As in the derivation set, where there was a mismatch between the
genotype and phenotype, isolates had repeat susceptibility tested by gra-
dient diffusion (“discordant repeat”). Possible explanations for the re-
maining discordant results were explored by testing for penicillinase pro-
duction with nitrocefin discs (15) and manually inspecting sequences for
the presumed resistance-encoding genes or mutations to give an amended
algorithm for future testing (v2.1).
Study accession number. The sequences reported in this paper have
been deposited in the European Nucleotide Archive Sequence Read Ar-
chive under study accession number ERP004655.
RESULTS
Derivation set. WGS and routine laboratory antimicrobial sus-
ceptibility testing results were available for 506 isolates, with 46
different sequence types found by in silico MLST. Using the initial
v1.0 algorithm, 439 isolates (87%) had complete concordance be-
tween the genotype and phenotype for all antimicrobial agents
tested. The remaining 67 isolates had a total of 123 discrepancies.
For five of these isolates, the frozen bacterial stocks were found to
be contaminated with other organisms (one isolate with Proteus
sp. and four isolates with coagulase-negative staphylococci), and
further confirmatory testing could not be performed. These iso-
lates were excluded from further analysis, leaving 501 isolates in
the derivation set. Repeating the susceptibility testing for the isolates
with phenotype/genotype mismatches reduced the error rate, with a
total of 71 discrepancies in the 49 isolates remaining (Fig. 1).
We noted a high VME rate for penicillin, with 9 (1.8%) isolates
apparently resistant to penicillin (MIC  0.12 mg/liter) in the
absence of the blaZ gene based on80% relative coverage in WGS
data. However, all 9 isolates were positive for blaZ by PCR. On
manual inspection of the sequences, we found that the blaZ gene
was in fact present on small sequence contigs (300 bp) or contigs
with low coverage (depth of cover  5) which did not meet the
algorithm quality standard and had therefore been excluded. In-
cluding these short or low-coverage contigs in the algorithm
(v2.0) improved predictions (with relative coverage as low as 30%
associated with phenotypic resistance). This phenomenon was
also noted for fusidic acid, where the inclusion of low-quality
contigs for the fusB and far genes improved prediction of pheno-
type. This was not the case for the remaining genes associated with
mobile elements in the panel where lowering the relative coverage
threshold substantially increased false-positive results.
Using this revised genotypic prediction method (v2.0), we
found 31 persistent discrepancies in 28 isolates across all antimi-
crobials in the derivation set (Fig. 1 and Table 4). There were 22
very major errors (0.4% VME rate) and 9 major errors (0.2% ME
rate). The overall sensitivity and specificity were 0.98 (95% confi-
dence interval [95% CI], 0.97 to 0.99) and 1.00 (95% CI, 0.99 to
1.00), respectively.
Blind validation set and genotypic prediction method v2.0.
For the 491 isolates in the validation set, 61 different sequence
types were identified by in silico MLST. The most frequent se-
quence types were ST22 (13%) and ST30 (12%). Fifty-seven iso-
lates were MRSA (12%). There were 60 errors in 48 isolates out of
5,193 antimicrobial susceptibilities tested (Fig. 1 and Table 5).
There were 25 VMEs: 6 for ciprofloxacin, 4 for erythromycin, 2 for
clindamycin, 4 for fusidic acid, 3 for penicillin, 2 for methicil-
lin, 2 for gentamicin, and 2 for trimethoprim. Of the 35 major
errors, 25 were for penicillin. The very major error rate was
0.5%, and the major error rate was 0.7%. The overall sensitivity
was 0.97 (95% CI, 0.95 to 0.98), and the overall specificity was
0.99 (95% CI, 0.98 to 1). Further details for each of the isolates
with discrepant results are given in Tables 6 (penicillin) and 7
(other antimicrobial agents).
(i) Penicillin. A total of 382 isolates were penicillin resistant
(78%). Of the 3 very major errors (Table 5), one isolate was sus-
ceptible on repeat testing (MIC of 0.06 mg/liter), while the other 2
were confirmed as resistant by Etest (MICs of 0.5 mg/liter and 0.25
mg/liter).
Although by using the prototype genotypic prediction method,
we found a high rate of very major errors for penicillin, using the
lower relative coverage (30%) threshold to define resistance for
v2.0 resulted in a high rate of major errors (5%), illustrating the
inherent trade-off between sensitivity and specificity for any algo-
rithm.
Of the 25 isolates with major errors (blaZ positive but sus-
FIG 1 Comparison of percentages of errors for the derivation and validation
sets, illustrating the change in error rate with repeat phenotyping and with
optimized algorithm versions. Error rates for resistant and susceptible isolates
are shown for each step of algorithm development: in the derivation set, the
error rate was decreased by repeat susceptibility testing (discordant rpt). The
VME rate was reduced by adjusting the algorthm parameters (v2.0), although
this resulted in a slight increase in the ME rate. In the validation set, error rates
were relatively low to start with and were improved further by repeat testing of
the discordants (v2.0 discordant rpt) and by incorporating the novel blaZ
mutations (v2.1).
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ceptible by initial phenotyping), 2 were penicillin resistant
when retested by Etest (MICs of 0.25 mg/liter) and were also
positive for penicillinase production. Eleven isolates were pos-
itive for penicillinase production at 10 min, and a further 3
isolates were weakly positive (i.e., positive after 2 h). Nine re-
maining isolates with blaZ had no penicillinase activity on
nitrocefin disc testing and had susceptible MICs by gradient
diffusion (0.12 mg/liter). Inspection of the blaZ genes found
single-base-pair insertions in 2 cases (positions 256 and 436,
respectively, relative to the reference sequence), causing a
frameshift in the translated protein which may explain the lack
of enzymatic activity. Similarly, 4 further isolates had identical
deletions at position 99, again resulting in a frameshift and
premature termination and correlating with a complete ab-
sence of pencillinase activity. We did not find any of these
mutations in the blaZ-positive, fully phenotypically resistant
isolates. Revising the algorithm for blaZ alone to define pres-
ence (30% coverage) of blaZ with these insertions/deletions
TABLE 4 Derivation set resultsa
Antimicrobial
agent
No. of isolates resistant by
phenotype
No. of isolates susceptible
by phenotype
Total no.
of isolates
Very major
error rate
(%)
Major
error rate
(%)
Sensitivity
(95% CI)
Specificity
(95% CI)
Susceptible
by genotype
Resistant by
genotype
Susceptible
by genotype
Resistant by
genotype
Penicillin 4 438 59 0 501 0.8 0 0.99 (0.98–1.00) 1.00 (0.92–1.00)
Methicillin 1 158 341 1 501 0.2 0.2 0.99 (0.96–1.00) 1.00 (0.98–1.00)
Ciprofloxacin 7 165 326 3 501 1.4 0.6 0.96 (0.91–0.98) 0.99 (0.97–1.00)
Erythromycin 1 133 366 1 501 0.2 0.2 0.99 (0.95–1.00) 1.00 (0.98–1.00)
Clindamycin 0 88 89 0 177c 0 0 1.00 (0.95–1.00) 1.00 (0.95–1.00)
Tetracycline 0 28 473 0 501 0 0 1.00 (0.85–1.00) 1.00 (0.99–1.00)
Vancomycin 0 0 501 0 501 0 0 N/Ad 1.00 (0.99–1.00)
Fusidic acid 3b 38 458 2 501 0.6 0.4 0.93 (0.79–0.98) 1.00 (0.98–1.00)
Trimethoprim 5 10 308 0 323 1.5 0 0.67 (0.39–0.87) 1.00 (0.98–1.00)
Gentamicin 0 7 494 0 501 0 0 1.00 (0.60–1.00) 1.00 (0.99–1.00)
Mupirocin 0 2 174 2 178 0 1.1 1.00 (0.20–1.00) 0.99 (0.96–1.00)
Rifampin 1 2 498 0 501 0.2 0 0.67 (0.13–0.98) 1.00 (0.99–1.00)
Overall 22 1,069 4,087 9 5,187 0.2 0.4 0.98 (0.97–0.99) 1.00 (0.99–1.00)
a Comparison of results for individual antimicrobial agents for 501 carriage/bacteremia isolates by phenotype (Vitek or disc diffusion) and predicted susceptibility using v2.0
genotypic prediction method. The result (resistant or susceptible) by phenotype refers to Vitek or disc diffusion results, and the result by genotype refers to the predicted
susceptibility using the v2.0 genotypic prediction method.
b Two isolates had two nonsynonymous mutations in fusA not previously described in the literature (T326I plus E468V and T326I plus V90I) which may be responsible for the
observed phenotypes.
c One isolate failed to grow for clindamycin testing.
d N/A, not applicable.
TABLE 5 Validation set resultsa
Antimicrobial
agent
No. of isolates resistant by
phenotype
No. of isolates susceptible
by phenotype
Total no.
of isolates
Very major error
rate (%) (95%
CI)
Major error rate
(%) (95% CI)
Sensitivity
(95% CI)
Specificity
(95% CI)
Susceptible by
genotypeb
Resistant by
genotype
Susceptible by
genotype
Resistant by
genotypeb
Penicillin 3 (2) 379 84 25 (9) 491 0.6 (0.1–1.8) 5.1 (3.3–7.4) 0.99 (0.98–1.00) 0.77 (0.68–0.84)
Methicillin 2 (1) 55 432 2 (1) 491 0.4 (0.05–1.5) 0.4 (0.05–1.5) 0.96 (0.87–0.99) 1.00 (0.98–1.00)
Ciprofloxacin 6 (4) 64 420 1 (0) 491 1.2 (0.4–2.6) 0.2 (0.05–1.1) 0.91 (0.82–0.96) 1.00 (0.98–1.00)
Erythromycin 4 (2) 79 405 3 (3) 491 0.8 (0.2–2) 0.6 (0.1–1.8) 0.95 (0.87–0.98) 0.99 (0.98–1.00)
Clindamycin 2 (2) 77 2 0 81 2.5 (0.3–8.6) 0.0 (0–4.4) 0.97 (0.90–1.00) 1 (0.20–1.00)
Tetracycline 0 18 471 2 (2) 491 0.0 (0–0.7) 0.4 (0.05–1.5) 1.00 (0.78–1.00) 1.00 (0.98–1.00)
Vancomycin 0 0 491 0 491 0.0 (0–0.7) 0.0 (0–0.7) N/Ac 1.00 (0.99–1.00)
Fusidic acid 4 (4) 39 448 0 491 0.8 (0.2–2) 0.0 (0–0.7) 0.91 (0.77–0.97) 1.00 (0.99–1.00)
Trimethoprim 2 (2) 1 197 2 (1) 202 1.0 (0.1–3.5) 1.0 (0.1–3.5) 0.33 (0.02–0.87) 0.99 (0.96–1.00)
Gentamicin 2 (2) 2 487 0 491 0.4(0.05–1.5) 0.0 (0–0.7) 0.50 (0.09–0.91) 1.00 (0.99–1.00)
Mupirocin 0 2 489 0 491 0.0(0–0.7) 0.0 (0–0.7) 1.00 (0.20–1.00) 1.00 (0.99–1.00)
Rifampin 0 5 486 0 491 0.0 (0–0.7) 0.0 (0–0.7) 1.00 (0.46–1.00) 1.00 (0.99–1.00)
Overall 25 (19) 644 4,410 35 (16) 5,112 0.5 (0.3–0.7) 0.7 (0.5–0.9) 0.97 (0.95–0.98) 0.99 (0.99–1.00)
a Comparison of susceptibility results for 491 bacteremia and carriage isolates by phenotype (Phoenix/disc diffusion consensus result) and genotype prediction tool v2.0. The result
(resistant or susceptible) by phenotype refers to Phoenix or disc diffusion consensus results, and the result by genotype refers to the predicted susceptibility using the v2.0 genotypic
prediction method.
b Figures in parentheses are numbers of isolates with discrepant phenotype confirmed on repeat testing.
c N/A, not applicable.
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as susceptible (v2.1), only 3 isolates had wild-type blaZ with no
penicillinase production detected by any of the phenotypic test
methods, giving a major error rate of 0.6% which is in keeping
with the observed error rates for the other antimicrobial agents
in this study.
(ii) Methicillin. Fifty-seven isolates (12%) were MRSA by ini-
tial phenotype. We found 2 very major errors (0.4%) and 2 major
errors (0.4%) for methicillin. Of the very major errors, one isolate
was susceptible on repeat testing (MIC of 0.5 mg/liter), and sim-
ilarly, one of the isolates with a major error was resistant on repeat
testing (MIC of 16 mg/liter), reflecting either sample heterogene-
ity or more probably laboratory error. Both methicillin resistance
in the absence of mecA resulting from overexpression of penicilli-
nase (16) and methicillin susceptibility despite the presence of
mecA have been previously described (5, 17), potential explana-
tions for the 2 remaining errors. None of the isolates contained
mecC (18).
(iii) Ciprofloxacin. Seventy isolates were phenotypically resis-
tant (14%). In both derivation and validation sets, the highest
VME rate was seen for ciprofloxacin. For the validation set, this
was 6/491 (1.2%), with a major error rate of 0.2% (1/491). Two of
the 6 isolates with very major errors were susceptible on repeat
testing. For the four other isolates with discrepant results, we ex-
amined the grlB, gyrB, and norA genes but found no significant
mutations (19, 20). The single isolate with a major error was found
to be resistant on repeat testing (MIC of 2 mg/liter). Of the 64
isolates predicted to be resistant by genotype and resistant by phe-
notype, 60 had the amino acid substitutions S80F in grlA and S84L
in gyrA. Four isolates had S84L in grlA only.
(iv) Erythromycin and clindamycin. A total of 83 (17%) iso-
lates were resistant to erythromycin by phenotype. For these 83
isolates, we observed 4 very major errors (0.8%). Two of these
were susceptible on repeat testing (MICs of 0.75 mg/liter), but the
other 2 were confirmed as resistant. There were 3 major errors
(0.6%) which were all confirmed as susceptible (MICs, 0.25 to 5
mg/liter). Two had ermC detected by BLAST, and one had ermA.
For the concordant resistant isolates, 37 had ermA alone, 37 had
ermC alone, 1 had ermT, 2 had msrA alone, 1 had ermC and msrA,
and 1 had ermC and ermA. None of the isolates had ermB. Out of
81 confirmed erythromycin-resistant isolates, 45 were resistant to
clindamycin by disc diffusion and 36 were susceptible. Of these
isolates, 34 had inducible resistance by D-test and contained either
ermA, ermC, or ermT as described above. The two isolates that
were resistant to erythromycin but susceptible to clindamycin
contained msrA only. There were 2 very major errors (same iso-
lates as for erythromycin VMEs). We did not observe any corre-
lation between erm variant and inducibility of clindamycin resis-
tance. We did not find vga(A)LC in any of the isolates (21).
(v) Tetracycline. Eighteen isolates were phenotypically resis-
tant (4%). Two major errors were seen for tetracycline (0.4%),
and both isolates were confirmed susceptible by Etest. One isolate
had tetK detected by BLAST (MIC of 0.19 mg/liter), and the other
had tetM (MIC of 0.75 mg/liter).There were no very major errors.
Of the 18 concordant resistant isolates, 16 had tetK, 1 had both
tetK and tetL, and 1 had tetM.
(vi) Vancomycin. Vancomycin resistance was not identified in
our isolates either phenotypically or genotypically. Consequently,
although the specificity of the method was 1.00, its sensitivity is
not estimable due to the rarity of vanA-mediated resistance. To
investigate the possibility of intermediate resistance missed by
phenotyping, post hoc we also screened the collection for recently
published mutations in the yycG gene (22) found to be associated
with intermediate MICs in laboratory mutants but did not iden-
tify these mutations in any isolate.
(vii) Fusidic acid. Forty-three isolates were phenotypically re-
sistant (9%). Four very major errors were observed for fusidic
acid. In 2 cases, manual examination of the sequences revealed
single point mutations in the chromosomal fusA gene, predicted
to result in the amino acid substitution of isoleucine for valine at
position 90. This substitution has been reported in both suscepti-
ble and resistant isolates (23), and therefore, its role in resistance is
unresolved. One resistant isolate had a substitution of serine for
threonine at position 656 (predicted sensitive on genotyping
based on a review of the literature). Since the substitution of lysine
for threonine at the same position is associated with full pheno-
typic resistance (23), this may explain the discrepancy seen in this
case.
(viii) Trimethoprim. Phenotypic testing for trimethoprim re-
sistance was performed for only 202 isolates, as it is not routinely
tested in Brighton, and it was not part of the BD Phoenix panel
used. Results are therefore taken from Oxford isolates, tested by
disc diffusion testing only. Three isolates were phenotypically re-
sistant (2%). There were 2 very major errors (1%) and 2 major
errors. Both isolates with very major errors were susceptible on
repeat testing (performed by disc diffusion only), and 1 isolate
with a major error was resistant on repeat testing.
(ix) Gentamicin. Four isolates were phenotypically resistant
TABLE 6 Results for MICs, nitrocefin disc testing, and blaZ variants for
isolates with discrepant results for penicillin in the validation set by the
v2.0 genotype prediction method
Isolatea
In silico
MLST
Initial
consensus
phenotypeb
MIC
(mg/liter)
Nitrocefin
disc test
result
blaZ variantc
10
min
120
min
C00001124 ST45 S 0.12   InsA436
C00001241 ST30 S 0.12   InsA256
C00001144 ST30 S 0.12   A99
C00001203 ST30/36 S 0.06   A99
C00013228 ST30 S 0.06   A99
C00013375 ST7 S 0.12   A99
C00001080* ST22 S 0.12   Similar to wild type
C00001092* ST2417 S 0.12   Similar to wild type
C00001112 ST2438 S 0.25   Similar to wild type
C00001148 ST1 S 0.12   Similar to wild type
C00001158 ST582 S 0.12   Similar to wild type
C00001142 ST582 S 0.12   Similar to wild type
C00001192 ST2417 S 0.12   Similar to wild type
C00001199 ST30 S 0.12   Similar to wild type
C00001205 ST30 S 0.06   Similar to wild type
C00001217 ST30 S 0.12   Similar to wild type
C00001231 ST22 S 0.12   Similar to wild type
C00001266 ST188 S 0.12   Similar to wild type
C00012754 ST20 S 0.25   Similar to wild type
C00001277 ST2445 S 0.12   Similar to wild type
C00013249 ST45 S 0.06   Similar to wild type
C00001093 ST15 S 0.12   Similar to wild type
C00001104 ST8 S 0.023   Similar to wild type
C00001111 ST5 S 0.12   Similar to wild type
C00001182 ST5 S 0.12   Similar to wild type
C00001147* ST22 R 0.5   Absent
C00012780 ST97 R 0.25   Absent
C00013232 ST7 R 0.06   Absent
a Isolates with discrepancies for one or more other antimicrobial agents are indicated by
an asterisk.
b S, sensitive; R, resistant.
c InsA436, insertion of A at position 436; A99, deletion of A at position 99.
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(1%). There were 2 very major errors, and resistance was con-
firmed by repeat testing (MICs of 24 mg/liter and 3 mg/liter). We
did not find aacA-aphD in either isolate, and they were also neg-
ative for aadD, aadE, and aphA3. The low frequency of resistance
in this collection means the evaluation is underpowered, which
makes accurately estimating the overall sensitivity impossible.
(x) Mupirocin and rifampin. Two isolates (0.4%) and 5 (1%)
isolates were resistant to mupirocin or rifampin, respectively.
There were no errors observed; however, the relatively low resis-
tance rates limit the power of the evaluation. Mupirocin resistance
in both cases was attributable to mupA.
DISCUSSION
We have developed and tested a method for genotypic prediction
of antimicrobial susceptibility phenotype from whole-genome se-
quencing within a single species, using substantial derivation (n
501) and validation (n  491) sets. Our goal was to develop a
method with direct relevance to clinical practice, and therefore,
our prediction tool is based on genetic mechanisms that have been
reported in clinical isolates, rather than including the very large
number of potential resistance determinants in existing databases
such as ResFinder (24) and CARD (Comprehensive Antibiotic
Resistance Database) (25), many of which have not been pheno-
typically verified in clinical isolates. Excluding phenotypic errors
and isolates with multiple discrepancies, the final results show
highly promising concordance, with a very major discrepancy rate
of 8/652 (1.2%) and a major discrepancy rate of 13/4,423 (0.3%),
comparable with the error rates for current phenotypic method-
ologies (26, 27) and within the acceptable limits set by the U.S.
Food and Drug Administration (28) for marketing approval of
new susceptibility testing methods (1.5% very major discrep-
ancy rate,3% major discrepancy rate).
In both the derivation and validation sets, a substantial num-
ber (40%) of the initial observed errors were resolved by repeat
phenotypic susceptibility testing. This is shown in Fig. 1, which
illustrates the phenotype/genotype discrepancies on initial testing,
after repeat phenotyping, and after adjustment of the algorithm
for both the derivation and validation sets. Even when testing
according to published guidelines, occasional errors in reagent
and medium storage, incubation conditions, and inoculum den-
sity may contribute to variation in observed phenotype, and sim-
ilarly, inaccuracies in labeling, interpretation, and data entry are
TABLE 7 Details of antimicrobial discrepancies for validation set and genotype prediction tool v2.0
Type of error and
antimicrobial agent(s) Isolatea
Initial
consensus
phenotypeb
MIC (mg/liter)
and/or phenotype
on repeat testingb Genotyping details
Very major errors
Methicillin C00001115*# R 0.5 (S) No mecA or mecC detected
C00001162* R 16 No mecA or mecC detected
Ciprofloxacin C00013185 R 1.5 No significant gyrA or grlA mutation
C00001162* R 2 No significant gyrA or grlA mutation
C00001092* R 2 No significant gyrA or grlA mutation
C00001115* R 2 No significant gyrA or grlA mutation
C00001105# R 0.125 (S) No significant gyrA or grlA mutation
C00001109# R 0.125 (S) No significant gyrA or grlA mutation
Erythromycin C00001147# R 0.75 (S) No erm or msrA gene detected
C00013384# R 0.75 (S) No erm or msrA gene detected
Erythromycin/clindamycin C00001224 R/R 2/ND No erm or msrA gene detected
C00001162* R/R 3/ND No erm or msrA gene detected
Fusidic acid C00013212 R R (disc only) V90I mutation in fusA
C00013194 R R (disc only) V90I mutation in fusA
C00001259 R R (disc only) Wild-type fusA, no fusB or far detected
C00001276 R R (disc only) T656S substitution in fusA
Trimethoprim C00001092*# R S (disc only) Wild-type dfrB, no dfrA or dfrG detected
C00001235# R S (disc only) Wild-type dfrB, no dfrA or dfrG detected
Gentamicin C00001115* R 24 No aacA-aphD, aadD or aadE, or aphA3 detected
C00013331 R 3 No aacA-aphD, aadD or aadE, or aphA3 detected
Major errors
Methicillin C00001222# S 16 (R) mecA gene detected, 100% relative coverage
C00001080* S 0.3 mecA gene detected, 100% relative coverage
Ciprofloxacin C00001080*# S 2 (R) S80F mutation in grlA, S84l mutation in gyrA
Erythromycin C00001249 S 0.25 ermA gene detected, 100% relative coverage
C00001189 S 0.25 ermC gene detected, 100% relative coverage
C00001080* S 0.5 ermC gene detected, 100% relative coverage
Tetracycline C00012796 S 0.19 tetK gene detected, 100% relative coverage
C00001247 S 0.75 tetM gene detected, 95% relative coverage
Trimethoprim C00001240 S S (disc only) H31N mutation in dfrB, usually confers resistance
C00001123# S R (disc only) dfrG gene detected, 100% relative coverage
a Isolates with discrepancies for two or more antimicrobial agents are indicated by an asterisk after the isolate name. Isolates for which the phenotype matched the genotype on
repeat testing are indicated by a hash symbol (#) after the isolate name.
b R, resistant; S, sensitive. Erythromycin and clindamycin were tested; the first phenotype or MIC is for erythromycin, and the second is for clindaymycin. ND, not done.
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liable to occur in any system which is not fully automated. Some of
these factors may also contribute to the genotyping results, and
this is supported by the fact that several isolates were discordant
for multiple antimicrobial agents, suggesting a labeling or storage
error.
The most problematic antimicrobial agent was penicillin, with
an unacceptably high very major error rate (1.8%) using v1.0 in
the derivation set and an unacceptably high major error rate (5%)
in the validation set using v2.0. This may be due to the variable
location of blaZ, which may be on a plasmid or integrated into the
chromosome (29). Isolates with chromosomally integrated blaZ
are likely to have average coverage in the sequencing reads, while
isolates with plasmid-carried copies may have very high (if multi-
ple copies are carried) or very low (because of poor mapping to the
reference) coverage in that region. As a result, these regions may
be rejected as poor quality by the assembly software, because they
fall outside the coverage levels of the rest of the genome. This
problem may be overcome in future with longer reads or alterna-
tive methods for de novo assembly; however, our results highlight
that relative coverage cutoff values may need to be set individually
based on gene location. Conversely, in the validation set, we found
that most of the major errors were due to a lack of concordance
between penicillinase production and disc or broth dilution test-
ing (30). We also identified three novel blaZ frameshift mutations
that were associated with susceptibility despite the presence of the
gene. Similar frameshift deletions have been reported in blaZ-
positive, penicillin-susceptible isolates from cows with mastitis
(31).
Relatively high very major error rates (1.2%) were also seen for
ciprofloxacin. Staphylococcal resistance to quinolones is predom-
inantly due to point mutations in the grlA and gyrA genes (19).
Low-level resistance may result from mutations in grlB or gyrB or
alterations in expression of the efflux pump NorA (20). However,
in most cases, these are in combination with grlA or gyrA muta-
tions, and consequently, the overall phenotypic effect is difficult to
predict. All isolates in this study contained the norA gene, but no
correlation was seen between quinolone resistance and the norA
gene or its known regulators, or the grlB or gyrB gene. Further
studies may be able to elucidate the contribution of these to overall
quinolone resistance in S. aureus.
There remains a very small subset of isolates where the genetic
basis for an antimicrobial phenotype of the organism was not clear
(15/48, excluding presumed phenotyping errors or identified
novel variants). If not due to human error, these may be due to
sequencing or assembly error, for example a miscalled base at a
critical position. However, for S. aureus, our group has sequenced
multiple replicates of strain MRSA 252 for comparison with a
capillary sequenced high-quality reference sequence of this ge-
nome (GenBank accession no. BX571856.1). The in-house esti-
mated false-positive rate (detection of a spurious variant) for our
bioinformatics pipeline was previously estimated to be 2.5 109
per nucleotide, i.e., 0.0075 per genome (32). Consequently, al-
though an incorrect susceptibility prediction may in theory occur
because of a sequencing error, in practice we anticipate that the
impact of this will be extremely small.
A more likely explanation for the discrepancies may be as
yet unidentified alterations in regulatory regions or alternative
resistance mechanisms. This highlights a major challenge for in
silico resistotyping, since a query-based method cannot recog-
nize novel variants that are not in the relevant database. Fur-
thermore, gene expression is the result of complex interactions
between transcription promoters, repressors, and other regu-
latory molecules, which may be remotely located from the gene
itself. Phenotypic assays address these challenges by measuring
the overall combined impact of all these mechanisms, although
it is important to recognize that factors resulting in delayed
transcription may cause isolates to be falsely identified as sus-
ceptible, as we found for penicillin.
Therefore, it is unlikely that WGS will be able to replace phe-
notypic methods entirely, and some form of phenotypic surveil-
lance will need to be maintained, for example based on clusters of
treatment failures. However, the need for routine phenotyping
should diminish as examination of WGS and phenotyping data
for isolates with apparently novel mutations or with nonfunction-
ing resistance genes elucidate the contribution of the underlying
genetics. This new knowledge can then be added to resistance
determinant databases and absorbed into WGS investigations, as
demonstrated by the improved specificity resulting from the in-
corporation of the novel blaZ variants above into the algorithm.
The huge potential of WGS data lies in its completeness: once
sequenced, a genome can be accessed repeatedly to query for novel
genes of interest as these arise (e.g., by our scan for recently pub-
lished yycG gene mutations [22]).
The cost and turnaround time for WGS have fallen rapidly in
recent years, with the current full economic cost of sequencing a
single isolate estimated to be less than £40 ($65) (33) compared
with approximately £5 ($8) per sample using the BD Phoenix.
Current turnaround times are directly comparable, with next-
generation sequencers able to deliver results in 27 h (5) and the
likelihood that this will be reduced to a matter of hours in the near
future. The potential for full automation of WGS may also reduce
human error, as described above. Further, the same WGS can also
provide information about potential transmission (34), and the
same methods as used to identify resistance determinants could be
used to bioinformatically extract the presence/absence of viru-
lence genes (35).
The advances provided by WGS, combined with robust clinical
outcome data, should greatly enhance our understanding of the
genetic basis of antimicrobial resistance, with the potential for
identifying new antimicrobial drug targets. The consequent
promise of improved drug discovery in the face of current global
concern regarding emerging antimicrobial resistance makes the
prospect of routine use of WGS increasingly attractive.
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